DiaMedica Therapeutics Inc
NASDAQ:DMAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Chahua Modern Housewares Co Ltd
SSE:603615
|
CN |
DiaMedica Therapeutics Inc
Depreciation & Amortization
DiaMedica Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Depreciation & Amortization
$43k
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
27%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
See Also
What is DiaMedica Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
43k
USD
Based on the financial report for Sep 30, 2025, DiaMedica Therapeutics Inc's Depreciation & Amortization amounts to 43k USD.
What is DiaMedica Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
27%
Over the last year, the Depreciation & Amortization growth was 19%. The average annual Depreciation & Amortization growth rates for DiaMedica Therapeutics Inc have been 20% over the past three years , 15% over the past five years , and 27% over the past ten years .
